Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of HTD1801 in Patients With Type 2 Diabetes Mellitus Who Have Poor Glycemic Control After Dietary and Exercise Interventions

NCT06350890 is registered in ClinicalTrials.gov with Shenzhen HighTide Biopharmaceutical Ltd. as lead sponsor.

NCT NCT06350890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06350890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of HTD1801 in Patients With Type 2 Diabetes Mellitus Who Have Poor Glycemic Control After Dietary and Exercise Interventions
Lead sponsor
Shenzhen HighTide Biopharmaceutical Ltd.
Phase
Phase 3
Overall status
Completed
Start date
November 5, 2023
Completion date
August 4, 2025
Enrollment
408 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

t2dm (type 2 diabetes mellitus)